Following on from information provided to NICE by the company in October 2019, the appraisal of Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1481
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 11 October 2019 | Suspended. Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer |
| 11 October 2019 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual